Successful Completion of Phase 2 COVID Trial for Antiviral Drug BIT225

Biotron Limited (ASX: BIT) has successfully completed the Phase 2 clinical trial for its antiviral drug, BIT225, targeting COVID-19. The trial, designed based on FDA guidance, aimed to assess the effects of 7 days of BIT225 treatment within 3 days of COVID-19 symptom onset. The drug exhibited promising results against SARS-CoV-2, significantly reducing viral load and preventing a cytokine storm in a mouse model.

All participants have completed dosing, marking the clinical phase's conclusion. Biotron's Managing Director, Michelle Miller, expressed satisfaction with the swift completion of recruitment and dosing within three months. Focus now shifts to analyzing trial samples, with preliminary results expected in September 2023. Biotron focuses on researching, developing, and commercializing drugs for significant viral diseases, with ongoing efforts in HIV-1, COVID-19, and other virus-related programs.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com